Eton Pharmaceuticals, Inc. (ETON): M&A transaction — Eton noncompliant with SEC reporting after Increlex acquisition; unable to provide audited financials

Eton Pharmaceuticals, Inc.

Acquisition of Increlex from Ipsen closed Dec 19, 2024; must be accounted for as business combination.
Historical financial statements for Increlex do not exist; Eton cannot create them.
Filed SEC waiver request for Item 9.01 financial statement requirement.
Noncompliance renders Eton ineligible for Form S-3 and substantially curtails capital raising.
Until waiver granted or financials filed, no new registration statements can be declared effective.

item 9.01 item 2.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Eton Pharmaceuticals, Inc. completed an acquisition involving Ipsen S.A. (closed 2024-12-19).

Action: acquisition
Counterparty: Ipsen S.A.
Closing: 2024-12-19

Exact text from the filing

on December 19, 2024, Eton Pharmaceuticals, Inc. (the "Company") completed its purchase (the "Acquisition") of the Increlex product from Ipsen S.A. ("Ipsen").

View on SEC.gov

Browse all m&a transactions →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-006678

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.